120 related articles for article (PubMed ID: 9127302)
1. The coupling of anisotropy and radial dose functions for 103Pd and 125I for use with a commercial treatment planning system.
Prete JJ; Bice WS; Dubois DF; Prestidge BR
Med Phys; 1997 Apr; 24(4):523-5. PubMed ID: 9127302
[TBL] [Abstract][Full Text] [Related]
2. Anisotropy functions for 103Pd, 125I, and 192Ir interstitial brachytherapy sources.
Nath R; Meigooni AS; Muench P; Melillo A
Med Phys; 1993; 20(5):1465-73. PubMed ID: 8289730
[TBL] [Abstract][Full Text] [Related]
3. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
4. More accurate fitting of 125I and 103Pd radial dose functions.
Taylor RE; Rogers DW
Med Phys; 2008 Sep; 35(9):4242-50. PubMed ID: 18841874
[TBL] [Abstract][Full Text] [Related]
5. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
Rivard MJ; Coursey BM; DeWerd LA; Hanson WF; Huq MS; Ibbott GS; Mitch MG; Nath R; Williamson JF
Med Phys; 2004 Mar; 31(3):633-74. PubMed ID: 15070264
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
Bohm TD; DeLuca PM; DeWerd LA
Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
[TBL] [Abstract][Full Text] [Related]
7. Fitting and benchmarking of dosimetry data for new brachytherapy sources.
Furhang EE; Wallace RE
Med Phys; 2000 Oct; 27(10):2302-6. PubMed ID: 11099198
[TBL] [Abstract][Full Text] [Related]
8. On the use of apparent activity (Aapp) for treatment planning of 125I and 103Pd interstitial brachytherapy sources: recommendations of the American Association of Physicists in Medicine radiation therapy committee subcommittee on low-energy brachytherapy source dosimetry.
Williamson JF; Coursey BM; DeWerd LA; Hanson WF; Nath R; Rivard MJ; Ibbott G
Med Phys; 1999 Dec; 26(12):2529-30. PubMed ID: 10619235
[No Abstract] [Full Text] [Related]
9. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
10. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
Bannon EA; Yang Y; Rivard MJ
Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
12. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy dosimetry parameters calculated for a new 103Pd source.
Rivard MJ; Melhus CS; Kirk BL
Med Phys; 2004 Sep; 31(9):2466-70. PubMed ID: 15487726
[TBL] [Abstract][Full Text] [Related]
15. Anisotropy functions for 125I and 103Pd sources.
Weaver K
Med Phys; 1998 Dec; 25(12):2271-8. PubMed ID: 9874818
[TBL] [Abstract][Full Text] [Related]
16. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States.
Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387
[TBL] [Abstract][Full Text] [Related]
17. Experimental determination of dosimetric characterization of a newly designed encapsulated interstitial brachytherapy source of 103Pd-model Pd-1.
Nath R; Yue N; Roa E
Med Phys; 2002 Oct; 29(10):2433-4. PubMed ID: 12408318
[TBL] [Abstract][Full Text] [Related]
18. Functional fitting of interstitial brachytherapy dosimetry data recommended by the AAPM Radiation Therapy Committee Task Group 43. American Association of Physicists in Medicine.
Furhang EE; Anderson LL
Med Phys; 1999 Feb; 26(2):153-60. PubMed ID: 10076967
[TBL] [Abstract][Full Text] [Related]
19. The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd.
Lindsay P; Battista J; Van Dyk J
Med Phys; 2001 Mar; 28(3):336-45. PubMed ID: 11318315
[TBL] [Abstract][Full Text] [Related]
20. Dose rate constant and energy spectrum of interstitial brachytherapy sources.
Chen Z; Nath R
Med Phys; 2001 Jan; 28(1):86-96. PubMed ID: 11213926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
